Skip to content
All Sections
Subscribe Now
65°F
Sunday, September 22nd 2024
e-Edition
Home Page
Close Menu
News
News
Crime and Public Safety
Investigative Reporting
Politics
Health
Environment
Business
Best Reviews
Housing
Jobs
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Olympics
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Puzzles
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Close Menu
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
65°F
Sunday, September 22nd 2024
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
Latest Trump news
Latest on wildfires
Murder suspect shoots self
LB's hotel room boom
High School Football
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Stoke Therapeutics, Inc.
< Previous
1
2
Next >
Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome
September 10, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
September 04, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Present at Upcoming Investor Conferences in September
September 03, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
September 03, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 16, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
August 07, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 16, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 18, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
June 03, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 17, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 06, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
April 29, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
April 17, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 04, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
March 27, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Proposed Public Offering
March 26, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 25, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
March 25, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
January 17, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024
January 08, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting
December 01, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting
November 21, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
November 07, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 17, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
September 21, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Appoints Ian Smith to its Board of Directors
September 20, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress
September 05, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
August 07, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close